Today's top stock ideas (Fri, Nov 17)

👋 Good Morning and happy Friday!

As a reminder, Fridays are CEO Watcher day. I send the free newsletter that includes the top 3 insider trades from the week every Friday (I track all the historical insider trades and calculate their returns to know which insiders buy their stock before it pops).

Today, our AI read and summarized 122 stock ideas, 1407 news articles, and 85 insider trades and found:

  • An analyst report on $CRL with a 37% upside (featured stock idea)

  • The CEO of $CRL also bought $1M of the stock (insider trade)

  • Jobless claims climb to three-month high (news)

  • and much more…

Thanks for reading! Have a great day.

Connor

* If you missed yesterday’s email, don’t forget to read it here

TODAY’S SPONSOR

+15 POINTS FOR CLICKING SPONSORED LINK - WEEKLY TOURNAMENT

Real estate investing creates the most millionaires…

And now CalTier makes it as easy as investing in stocks.

CalTier gives you the power to invest in cash-flowing commercial real estate, like apartment buildings, right from your phone. And you can start with just $500!

They have been written about in publications like Seeking Alpha, Yahoo Finance, Morningstar, and more! And as of October, the fund has paid out 23 consecutive distributions to investors.*

Start building your real estate portfolio today!

*Past performance is not a guarantee of future performance.

FEATURED STOCK IDEA

ANALYST REPORT

Charles River Laboratories: Cautious Client Spending Affects Near Term, but Long-Term Outlook Positive

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services.

Ticker: CRL | Price: $189.56 | Price Target: $260 (+37%) | Timeframe: N/A

💊 Drug Discovery | 📈 Bullish Idea

The CEO also just bought $1M of the stock as noted in the Insider Trades section.

Charles River Laboratories, a company with a narrow moat rating, reported a 4% increase in third-quarter revenue to $1.03 billion, despite headwinds from cautious client spending and macroeconomic challenges impacting its research models and services segment. The company showed sequential improvement in its safety assessment business, with a lower study cancellation rate and a better net book/bill ratio, indicating stabilization in the biotech funding environment, especially in venture capital investments. With the stock currently trading about 35% below our $260 fair value estimate and in the 5-star territory, we view it as undervalued. For 2023, we project a revenue growth of approximately 3% to $4.1 billion. Our positive long-term outlook is based on increasing demand for preclinical outsourcing services and Charles River's industry-leading position. The stock's current valuation is seen as an attractive entry point for long-term investors, considering the company’s strong market position in research models and discovery and safety assessment, and the expectation that the current macroeconomic challenges will stabilize in the forecast period.

Read the full article here (paywall). Read time: 8 min

POLL - FEATURED STOCK IDEA

+3 POINTS - WEEKLY TOURNAMENT

How do you rate the featured stock idea?

Login or Subscribe to participate in polls.

Yesterday’s Rating (link):

CRH plc ($CRH)

🟦🟦🟦⬜️⬜️ - Buy (39%)
🟦🟦🟦⬜️⬜️ - Pass (35%)
🟦🟦🟦⬜️⬜️ - Watchlist (26%)

* There are more stock ideas later in the email!

MARKET OVERVIEW

Are you short-term bullish or bearish on the market?

Login or Subscribe to participate in polls.

Yesterday: 58%

The indexes were pretty flat today except for the Russell small-cap index which dropped over 1.5%, but both the Yellowbrick poll and the CNN Fear v Greed index went up 2 points (and is right on the threshold to tip into the “Greed” category). Will be interesting to see if the little run we’ve been on is running out of steam.

STOCK MARKET NEWS

Today’s news is brought to you by Your Next Breakthrough. Get one idea, one question, and one exercise each week that could spark your next personal breakthrough. Sign up with 1-click here or subscribe on their site.

US FDIC to consider 'special assessment' for March bank failure losses - Reuters 

Jobless claims climb to three-month high of 231,000 in sign labor market is cooling - Market Watch 

Retail traders cash out as market rallies on bets of end to rate hikes - Reuters 

Amazon will allow auto dealers to sell cars on its site, starting with Hyundai - CNBC 

Gap blows past earnings estimates but offers muted holiday forecast against uncertain backdrop - CNBC 

Macy's profit beats as inventory and margins improve - CNBC 

Cruise is taking all its vehicles off public roads amid expanded safety probe, staff changes - CNBC 

* If you want all of the day’s most important stock market news, sign up for my free, daily email called Market Mornings.

QUIZ

+3 POINTS - WEEKLY TOURNAMENT

Which former Harper Professor and economist was known for the concept of 'creative destruction' in economics?

Login or Subscribe to participate in polls.

Yesterday’s Question (link): Before its rise to a tech giant, which company did Larry Ellison co-found in 1977, initially named Software Development Laboratories?

Answer: Oracle. It took six years before it named itself Oracle Systems Corporation to align itself more closely with its flagship product - Oracle Database. The name also drew from the 1977 CIA project codename that was its first customer.

INSIDER TRADES

The insider trades are brought to you by CEO Watcher (another free, weekly email I write). It’s the only newsletter that tracks insider returns to find the best ones.

A big director at CCC Intelligent Solutions ($CCCS) sold all of their holdings ($700M) (link)

A director at Madrigal Pharmaceuticals ($MDGL) bought $17.6M of stock (increasing their holdings by 11%) (link)

The CEO at Charles River Labs ($CRL) bought $1M (increased holdings by 2%) (link)

The acting CFO at Janux Therapeutics ($JANX) bought $5M (holdings increased 19%) (link)

A director at Bill Holdings ($BILL) bought $1M (holdings increased 92%) (link)

LINKS YOU’LL LOVE

+15 POINTS - WEEKLY TOURNAMENT

The S&P Real Estate sector makes up less than 5% of the S&P 500, its lowest ever (even lower than 2008)

* Sponsored link

SECRET QUESTION

+10 POINTS - WEEKLY TOURNAMENT

If you read this far, reply to this email with your answer to gain points for the weekly tournament. (Or if you’d rather not answer but still want the points, you can just reply and say hi!)

Secret Question: How old were you when you bought your first stock?

Attention Gmail Users: Gmail (and a few other email clients) cut off long emails and will probably cut off this email in the next section. You can read the rest of the email on the website by clicking the button below.

* If you don’t want any more of these emails, unsubscribe here.

SECRET QUESTION

+10 POINTS - WEEKLY TOURNAMENT

If you read this far, reply to this email with your answer to gain points for the weekly tournament. (Or if you’d rather not answer but still want the points, you can just reply and say hi!)

Secret Question: How old were you when you bought your first stock?

BONUS STOCK IDEAS

ANALYST REPORT

Healthpeak Properties, Inc.: Strong 3Q results and merger announcement

Healthpeak Properties is a self-administered real estate investment trust that invests directly or through joint ventures in private-pay healthcare facilities in the United States.

Ticker: PEAK | Price: $16.55 | Price Target: $30 (+81%) | Timeframe: N/A

🏠 Real Estate Investment | 💰 7.3% Dividend | 📈 Bullish Idea

Healthpeak Properties Inc. (NYSE: PEAK) delivered strong third-quarter 2023 results with a 5% increase in Funds From Operations (FFO) 'as adjusted' to $0.45 per share and announced an all-stock merger with Physicians Realty Trust (NYSE: DOC). This merger, expected to close in the first half of 2024, will add 291 healthcare properties to PEAK's portfolio, which is already 94.6% leased. Management raised its 2023 FFO guidance to $1.76-$1.78 per share from $1.73-$1.77, indicating a 1.7% growth from 2022. Despite recent share price declines, we maintain a BUY rating on PEAK with a target price of $30, viewing the stock as undervalued. The company's focus is now on its Life Science and Medical Office businesses, benefiting from increased demand for eldercare services and a shift to specialized outpatient centers. Healthpeak's solid demand in its Medical Office and Life Science segments, combined with the expected synergies from the Physicians Realty merger and a high dividend yield of about 7.3%, presents a strong investment opportunity, particularly for income-oriented investors.

Read the full article here (paywall). Read time: 8 min

HEDGE FUND

Polen Capital new small/mid-cap holding: TravelSky

TravelSky Technology Limited provides information technology solutions for aviation and travel industry in the People's Republic of China.

Ticker: OTC:TSYHY | Price: $16.18 | Price Target: N/A | Timeframe: N/A

🛩️ Aviation | 💻 Software | 📈 Bullish Idea

We initiated a position in TravelSky, a Chinese aviation software company similar to Amadeus in Europe. The company has an almost monopolistic position in China and benefits from increased domestic and international travel by Chinese citizens. Per capita consumption of air travel remains low in China and was particularly depressed during COVID-19. The company also benefits from the build-out of airports in the country by providing systems and software. We think valuation is very attractive and is arguably at less than 10x normalized earnings. We expect revenue recovery and corresponding margin expansion as travel resumes and the company monetizes various opportunities.

Read the full article here. Read time: 6 min

HEDGE FUND

Talkspace, Inc (TALK): A therapy company that needs rehab! Potential exaggerated revenues and shady practices.

Talkspace, Inc. operates as a virtual behavioral healthcare company. The company offers psychotherapy and psychiatry services through its platform to individuals, enterprises, and health plans through both business-to-business and business-to-consumer channels.

Ticker: $TALK | Price: $1.76 | Price Target: N/A | Timeframe: N/A

🧠 Online Therapy | 📉 Bearish Idea

Talkspace, an online therapy company, has seen its stock price surge by 170% as of November 6, 2023. However, this rapid growth is raising concerns due to a variety of issues. First, Talkspace recently settled for $8.5 million with investors who alleged they were misled in support of a SPAC merger with Hudson Executive Investment. This settlement raises doubts about the company's conduct. Additionally, the SEC questioned Talkspace's accounting practices, particularly regarding the use of questionable accounting measures, drawing parallels to issues seen in other companies. Their choice of an Israeli auditor, despite limited operations in Israel, has raised suspicions about their financial reporting. Concerns are also raised about the involvement of insiders in their Variable Interest Entities (VIEs) and the potential for funds to be directed back to the company through these entities. Furthermore, allegations of billing issues and questionable privacy policies, including data mining practices, have emerged. Google Trends data indicates a decline in Talkspace's popularity since its peak during the COVID-19 pandemic in 2020. In summary, Ragnarok Research believes Talkspace's stock is overvalued and faces numerous issues related to its business practices, accounting, ethics, and privacy concerns, which could lead to future troubles for the company.

Read the full article here. Read time: 8 min

+3 POINTS - WEEKLY TOURNAMENT

Which bonus stock idea was the most compelling to you?

Login or Subscribe to participate in polls.

Yesterday’s Poll Results (link):

🟩🟩🟩⬜️⬜️ Mastercard ($MA) [43%]

🟨🟨⬜️⬜️⬜️ Mader Group ($MAD.AX) [29%]

🟨🟨⬜️⬜️⬜️ Pubmatic ($PUBM) [28%]

Your Thoughts:

  • 💳 dana.*** ($MA): I believe in Mastercard's security, the product, and their growth from community investments.

WEEKLY TOURNAMENT

Gain points and earn prizes every week just for voting on the quizzes/polls, replying to this email, and clicking on ads/sponsored links!

🏆 This Week’s Leaderboard

  1. char**** (159 points)

  2. cguz*** (159 points)

  3. stoc**** (159 points)

Scoring

  • +3 points for voting in each poll

  • +10 points for replying to this email

  • +15 points for clicking on an ad/sponsored link

  • +50 points for referring a friend

* Learn more about the Weekly Tournament here

MY OTHER FREE NEWSLETTERS

Market Mornings (link): The fastest way to get the top stock market news each morning. We only send the headlines, so there is no fluff, politics, etc.

CEO Watcher (link): I built a tool that tracks all insider trades AND calculates their historical returns so that we know which insider trades are worth copying. The top insider trades are sent every Friday.

Intentional Dollar (link): Simple thoughts, tools, and questions to help move your money forward → published weekly, for free, from a professional Financial Advisor and CFP® (written by my friend)

INVITE YOUR FRIENDS

+50 POINTS - WEEKLY TOURNAMENT

If you enjoy the Yellowbrick Road newsletter, please share it with a friend :). Plus, you’ll get points for the Weekly Tournament!

THAT’S ALL FOLKS

+3 POINTS - WEEKLY TOURNAMENT

Thank you so much for reading today’s email! Your support is the only way I can write this email for free every day. Give me feedback in the poll below to earn 3 points for this week’s tournament.

Connor (@connorvo on Twitter)

How would you rate today's newsletter?

If you vote 1 or 3 stars, please leave a comment with what you didn't like so I can improve it!

Login or Subscribe to participate in polls.

Join the conversation

or to participate.